AMANDA SCHNEIDER: Open Payments
NPI 1588163943 · NEW ALBANY, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,191 in 104 payments from 37 companies in 2025. Trend: 2023 $1,327 · 2024 $1,077 · 2025 $2,191
Food & beverage: $2,116Education: $75
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 13 | $247 |
| Celgene Corporation | 8 | $208 |
| PFIZER INC. | 9 | $181 |
| ABBVIE INC. | 6 | $129 |
| Janssen Biotech, Inc. | 6 | $125 |
| Daiichi Sankyo Inc. | 6 | $110 |
| Incyte Corporation | 4 | $108 |
| SOBI, INC | 2 | $96 |
| Regeneron Healthcare Solutions, Inc. | 3 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $80 |
Products named: REBLOZYL, KISQALI, IBRANCE, Fabhalta, Venclexta, Enhertu, OPDIVO, JAKAFI.
Industry payments across IN — which companies pay providers there.
